Effect of Weight Loss on Cardiovascular Disease Risk Factors in Obese Women - Full Text View

Purpose

The purpose of this study is to examine the effect of weight loss and exercise on cardiovascular disease risk factors, specifically inflammation as measured by C-Reactive Protein and cardiac structure and function as measured by cardiac MRI, in Class II and III obese women during a 12 week training intervention.

Condition	Intervention
Obesity Cardiovascular Diseases	Behavioral: Diet Behavioral: Diet Plus Aerobic Training Behavioral: Diet plus Resistance Training

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention
Official Title:	The Effect of Weight Loss and Exercise on Cardiovascular Disease Risk Factors in Class II and III Obese Women

Resource links provided by NLM:

MedlinePlus related topics: Exercise and Physical Fitness Obesity Weight Control

U.S. FDA Resources

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:

Cardiovascular Disease Risk Factors [ Time Frame: 0 and 12 weeks ] [ Designated as safety issue: No ]
Inflammation as determined by C-Reactive Protein and Cardiac Structure and Function as defined by left ventricular mass, aortic pulse wave velocity, fibrosis, and ejection fraction.

Secondary Outcome Measures:

Weight Loss [ Time Frame: 0 and 12 weeks ] [ Designated as safety issue: No ]
Weight loss by diet alone, diet plus aerobic training, and diet plus resistance training.

Estimated Enrollment:	30
Study Start Date:	April 2011
Estimated Study Completion Date:	July 2011
Primary Completion Date:	May 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Diet Only	Behavioral: Diet Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day. Other Name: DIET
Experimental: Diet plus Aerobic Training	Behavioral: Diet Plus Aerobic Training Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1. Other Name: DIET+AT
Experimental: Diet plus Resistance Training	Behavioral: Diet plus Resistance Training Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand. Other Name: DIET+RT

Detailed Description:

To date, research investigating obesity, inflammation, and cardiovascular disease has utilized lifestyle interventions focused on weight loss and exercise among groups with BMI classifications of normal, overweight and mildly obese. A limitation of recent investigations is the failure to utilize participants who are significantly overweight. Those whose BMI classification extends to Class II and Class III obesity (BMI > 35.0, and BMI > 40.0) have not yet been studied at length, yet these individuals have been shown to be able to substantially improve their cardiovascular risk profiles without attaining a BMI below 25. Inactivity has been linked to increased adiposity and a trend toward higher levels of cardiovascular disease risk. It is necessary to study the relationships between weight loss and weight loss with added physical activity among Class II and Class III obese participants in order to gain a more thorough knowledge of the effects of BMI on circulating markers of inflammation and the cardiac structural and functional changes associated with weight loss among this population. A second limitation of the current research is the use of strictly progressive resistance training protocols. The protocols used have increased constantly in intensity or volume, if not both. Constant increases in intensity tend to lead to overtraining among participants, highlighting a need for more variation of intensity and volume in the training protocol in order to avoid stagnation and overtraining. Finally, no research has studied the specific impact of diet and resistance training on either CRP or cardiovascular adaptations.

Eligibility

Ages Eligible for Study:	30 Years to 55 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Female
30-55 years of age
BMI = 35.0-44.9 kg/m2

Exclusion Criteria:

Currently pregnant, pregnant in the past 6 months, or planning on becoming pregnant in the next 6 months.
Regularly exercising for greater than 60 minutes per week.
Taking prescription or over-the-counter medications that affect body weight, metabolism, blood pressure, or heart rate, such as psychotropic medications (e.g. zoloft, prozac, paxil, xanax) and medications that have metabolic effects (e.g. synthroid, wellbutrin, metformin).
Having physical limitations that hinder or prevent exercise.
Currently being treated for coronary heart disease, diabetes mellitus, hypertension, or cancer.
Having a resting systolic blood pressure of > 150mmHg of diastolic blood pressure of > 100mmHg or currently taking any medications that affect blood pressure or heart rate (i.e. beta blockers).
Currently enrolled in an exercise or weight control study or participating in an exercise or weight control study in the past 6 months.
Have lost and not regained > 5% body weight in the past 6 months.
Currently being treated for any psychological problems or taking any psychotropic medications.
Abnormal kidney functions, as per current institutional standard for gadolinium administration.
Known allergy to IV gadolinium, or the discovery of an allergic reaction to IV gadolinium at baseline.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01353001

Locations

United States, Pennsylvania
Physical Activity and Weight Management Research Center, Suite 600 Birmingham Towers
Pittsburgh, Pennsylvania, United States, 15203

Sponsors and Collaborators

University of Pittsburgh

Investigators

Principal Investigator:	Steven D Verba, MS	University of Pittsburgh
Study Director:	Blake D Justice, MS	University of Pittsburgh

More Information

No publications provided

Responsible Party:	Steven D. Verba/Graduate Student Researcher, University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT01353001 History of Changes
Other Study ID Numbers:	BSD-UPitt
Study First Received:	May 11, 2011
Last Updated:	May 11, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Pittsburgh:

Intervention Studies
Magnetic Resonance Imaging
C-Reactive Protein

Additional relevant MeSH terms:

Cardiovascular Diseases
Obesity
Weight Loss
Overnutrition
Nutrition Disorders

Overweight
Body Weight
Signs and Symptoms
Body Weight Changes

ClinicalTrials.gov processed this record on June 17, 2013